New coumarin–chalcone–triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation
RSC Advances · 2025 · 15 (59) · 51136-51161
DOI: 10.1039/d5ra07254a ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Advances, 2025. Verfasst von Fariba Peytam und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Tehran University of Medical Sciences and Health Services.
Abstract (Originalsprache)
Novel coumarin–chalcone–triazole hybrids were designed and synthesized as potent α-glucosidase inhibitors. Lead compound 20q showed exceptional enzymatic potency, strong selectivity, and remarkable in vivo antihyperglycemic activity.
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran.
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences Tehran Iran.
- Faculty of Pharmacy, Final International University Kyrenia via Mersin 10 Turkey TRNC Catalkoy Turkey.
- Eastern Mediterranean University, Faculty of Pharmacy TRNC, via Mersin 10 Turkey Famagusta Cyprus.
- Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran.
- Department of Bioinformatics and Systems Biology, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences Isfahan Iran.
ORCID-Profile: Somayeh Mojtabavi, Mohammad Ali Faramarzi, Alireza Foroumadi
Förderung
- Tehran University of Medical Sciences and Health Services
Zitieren
APA
Peytam, F., Norouzbahari, M., Akbari, M., Gülcan, H. O., Moradi, M., Mojtabavi, S., Faramarzi, M. A., Ghasemi, F., Torabi, M., Tehrani, M. B., Sheibani, V., Firoozpour, L., & Foroumadi, A. (2025). New coumarin–chalcone–triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation. RSC Advances, 15(59), 51136-51161. https://doi.org/10.1039/d5ra07254a
Vancouver
Peytam F, Norouzbahari M, Akbari M, Gülcan HO, Moradi M, Mojtabavi S, et al. New coumarin–chalcone–triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation. RSC Advances. 2025;15(59):51136-51161. doi:10.1039/d5ra07254a
BibTeX
@article{Peytam2025,
author = {Peytam, Fariba and Norouzbahari, Maryam and Akbari, Mahsa and Gülcan, Hayrettin Ozan and Moradi, Mahfam and Mojtabavi, Somayeh and Faramarzi, Mohammad Ali and Ghasemi, Fahimeh and Torabi, Mohammadreza and Tehrani, Maliheh Barazandeh and Sheibani, Vahid and Firoozpour, Loghman and Foroumadi, Alireza},
title = {New coumarin–chalcone–triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation},
journal = {RSC Advances},
year = {2025},
volume = {15},
number = {59},
pages = {51136--51161},
doi = {10.1039/d5ra07254a}
}
EUVIMED